Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe

Autor: Yasunori Oguma, Hiroshi Ito, Daisuke Yamazaki, Takashi Koyama, Hiroyuki Watanabe, Yutaka Terata, Kenji Iino, Masaru Ishida, Toshimitsu Kosaka, Kiyoshi Nobori
Rok vydání: 2012
Předmět:
Male
Endocrinology
Diabetes and Metabolism
Clinical Biochemistry
Coronary Disease
Pharmacology
Gastroenterology
Coronary artery disease
chemistry.chemical_compound
Endocrinology
High-density lipoprotein
Prospective Studies
Rosuvastatin Calcium
Aged
80 and over
Sulfonamides
biology
Anticholesteremic Agents
Secondary prevention
Middle Aged
Drug Combinations
Serum Amyloid P-Component
C-Reactive Protein
lipids (amino acids
peptides
and proteins)
Female
medicine.drug
Lipidology
Adult
medicine.medical_specialty
Statin
Clinical chemistry
medicine.drug_class
Drug Administration Schedule
Ezetimibe
Internal medicine
medicine
Humans
Rosuvastatin
Aged
Biochemistry
medical
Inflammation
business.industry
Cholesterol
Interleukin-6
Tumor Necrosis Factor-alpha
Research
Biochemistry (medical)
C-reactive protein
Cholesterol
HDL
Cholesterol
LDL
Fluorobenzenes
Pyrimidines
chemistry
biology.protein
Azetidines
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Zdroj: Lipids in Health and Disease
ISSN: 1476-511X
Popis: Background Statins are frequently administered to reduce low-density lipoprotein cholesterol (LDL-C) and vascular inflammation, because LDL-C and high sensitive C-reactive protein (hs-CRP) are associated with high risk for cardiovascular events. When statins do not reduce LDL-C to desired levels in high-risk patients with coronary artery disease (CAD), ezetimibe can be added or the statin dose can be increased. However, which strategy is more effective for treating patients with CAD has not been established. The present study compares anti-inflammatory effects and lipid profiles in patients with CAD and similar LDL-C levels who were treated by increasing the statin dose or by adding ezetimibe to the original rosuvastatin dose to determine the optimal treatment for such patients. Methods 46 patients with high-risk CAD and LDL-C and hs-CRP levels of >70 mg/dL and >1.0 mg/L, respectively, that were not improved by 4 weeks of rosuvastatin (2.5 mg/day) were randomly assigned to receive 10 mg (R10, n = 24) of rosuvastatin or 2.5 mg/day of rosuvastatin combined with 10 mg/day of ezetimibe (R2.5/E10, n = 22) for 12 weeks. The primary endpoint was a change in hs-CRP. Results Baseline characteristics did not significantly differ between the groups. At 12 weeks, LDL-C and inflammatory markers (hs-CRP, interleukin-6, tumour necrosis factor-alpha and pentraxin 3) also did not significantly differ between the two groups (LDL-C: R10 vs. R2.5/E10: -19.4 ± 14.2 vs. -22.4 ± 14.3 mg/dL). However, high-density lipoprotein cholesterol (HDL-C) was significantly improved in the R10, compared with R2.5/E10 group (4.6 ± 5.9 vs. 0.0 ± 6.7 mg/dL; p Conclusion Both enhanced therapies exerted similar anti-inflammatory effects under an equal LDL-C reduction in patients with high-risk CAD despite 2.5 mg/day of rosuvastatin. However, R10 elevated HDL-C more effectively than R2.5/E10. Trial registration UMIN000003746
Databáze: OpenAIRE
Externí odkaz: